Doctors info
Dr. Vijai Simha

Dr. Vijai Simha

MBBS, MD - Radiotherapy (Dec 2012), DM - Medical Oncology (July 2019), Post Graduate Diploma in Medical Law & Ethics (2014) | Consultant

14 years of experience
Book Consultation

Professional Overview

Dr. Vijai Simha is a Consultant in Medical Oncology with 6 years of experience, specializing in breast, urological, head and neck, gynaecological, gastrointestinal, and thoracic cancers. He completed MBBS at J.S.S. Medical College, MD Radiotherapy at PGIMER Chandigarh, and DM Medical Oncology at Tata Memorial Hospital. He holds multiple diplomas including PGDMLE, PGDIPRL (National Law School of India University, Bengaluru), clinical research, pharmacovigilance, clinical trials monitoring, and cancer genomics from Harvard University.

He has held senior residency roles at PGI and TMH and served as faculty at TMH. His areas of focus include postgraduate teaching, clinical research, and participation in national and international clinical trials, where he currently serves as Principal Investigator. He has authored several publications in peer-reviewed journals. He is a member of ISMPO, ESMO, and ESTRO. He is currently based in Bengaluru, where he continues his clinical, academic, and research work at Sri Shankara Cancer Hospital & Research Centre.

Research Publications

1. Osteosarcoma journey over two decades in India: Small steps, big changes

Authors: Bajpai J, Chandrasekharan A, Simha V, Mandal T, Shah K, Hingmare S, Rangarajan B, Shetty N, Vora T, Ghosh J, Rekhi B

Journal: Pediatric blood & cancer

Published: 2019 Sep

Additional Details: 66(9):e27877

2. Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma

Authors: Patil VM, Bhelekar A, Menon N, Bhattacharjee A, Simha V, Abhinav R, Abhyankar A, Sridhar E, Mahajan A, Puranik AD, Purandare N

Journal: Cancer Medicine

Published: 2020 Jul

Additional Details: 9(13):4676-85

3. Clinical–radiological features of methotrexate-induced subacute leukoencephalopathy in patients with acute lymphoblastic leukemia:'Panda eye sign'on diffusion weighted-magnetic resonance imaging

Authors: Mahajan A, Jain H, Simha V, Vaidya T, GV SK, Gupta A, Bagal B, Sengar M

Journal: Cancer Research, Statistics, and Treatment

Published: 2019 Jan 1

Additional Details: 2(1):28-33

4. Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers

Authors: Simha V, Patil V, Joshi A, Prabhash K, Noronha V

Journal: Cancer Research, Statistics, and Treatment

Published: 2019 Jul 1

Additional Details: 2(2):172-81

5. Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers

Authors: Simha V, Patil V, Joshi A, Prabhash K, Noronha V

Journal: Cancer Research, Statistics, and Treatment

Published: 2019 Jul 1

Additional Details: 2(2):172-81

6. Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers

Authors: Ramaswamy A, Ostwal V, Gupta K, Simha V, Toshniwal A, Shetty N, Nashikkar C, Mandavkar S, Gupta S

Journal: South Asian Journal of Cancer

Published: 2018 Oct

Additional Details: 7(04):219-22

7. Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients

Authors: Simha V, Patil VM, Joshi A, Noronha V, Talreja V, Dhumal S, Chandrasekharan A, Shrirangwar S, Prabhash K

8. Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer

Authors: Patil V, Joshi A, Noronha V, Agarwala V, Chougule A, Kanan S, Bhattacharjee A, Chandrasekharan A, Pande N, Simha V, Goud S

Journal: Oncotarget

Published: 2019 Oct 10

Additional Details: 10(59):6297

9. Palliative chemotherapy in carcinoma nasopharynx

Authors: Patil VM, Joshi A, Noronha V, Talreja V, Simha V, Dhumal S, Bandekar B, Chandrasekharan A, Prabhash K

Journal: South Asian Journal of Cancer

Published: 2019 Jul

Additional Details: 8(03):173-7

10. MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours

Authors: Mathranda SA, Kumar P, Kumar R, Srihari S, Diwaker R, Munirathnam V, Simha V, Anantharamu S, RN S, PS H, Veeraiyan D

11. Solitary fibrous tumour: A case series of a deceptively simple neoplasm in a tertiary care centre in South India

Authors: Rambhojun HD, Vijayanarasimha D, Velusamy S, Srihari SM, Venkataswamy C, Kumar RV, Srivatsa HG, Simha V, Srinath BS

Journal: Journal of Diagnostic and Academic Pathology

Published: 2025 Jul 1

Additional Details: 2(2):79-84

12. Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center

Authors: Appachu S, Diwaker RB, Vivek S, Simha VV

Journal: Indian Journal of Medical and Paediatric Oncology

Published: 2025 Apr

Additional Details: 46(02):168-73

Sri Shankara Cancer Hospital Footer Shankara Cancer Hospital & Research Center